CTRI/2023/10/058896
Recruiting
未知
Impact of SGLT-2 Inhibitors on Renal Function Among the Patients Undergoing Percutaneous Coronary Interventions with Type 2 Diabetes and Coronary Artery Disease: A Cohort Study - nil
GSM Institute of Pharmaceutical Science0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications
- Sponsor
- GSM Institute of Pharmaceutical Science
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \- \>18 years
- •Medication duration 3months \- 3years
- •T2DM with indication of PCI
- •Obstructive coronary artery disease, characterized by a \=50% narrowing in a major epicardial vessel, and who also have a clinical indication for undergoing PCI.
- •Willing to provide consent to participate in the study
- •eGFR range 50\-90 ml/min/1\.73m2
Exclusion Criteria
- •Auto immune disease
- •Chronic use of anti\-inflammatory medications.
- •Severe anemia
- •Cardiogenic shock
- •Use of nephrotoxic drugs
- •History of CIN
- •Use of contrast media less than 7 days
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 4
Effect of SGLT2 inhibitor on Renal Function and Urinary [TIMP-2] x [IGFBP7] in Patients Hospitalized for Acute Heart Failure; A Randomized Controlled TrailAcute kidney injury and urinary [TIMP-2] x [IGFBP7] in patient hospitalized for acute heart failureAcute kidney injury, urinary [TIMP-2] x [IGFBP7], nephrocheck, acute heart failure, acute decompensated heart failure, SGLT2 inhibitor, renal function, biomarkerTCTR20221003002/A66
Active, not recruiting
Phase 1
The RECEDE-CHF TrialType 2 diabetes and heart failureMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003968-39-GBniversity of Dundee/NHS Tayside23
Recruiting
Not Applicable
Investigation of renal protective effects of SGLT2 inhibitor by using renal doppler ultrasonographyJPRN-UMIN000028438Ogawa Red Cross Hospital60
Completed
Phase 3
Evaluation Renoprotective Effect SGLT2 inhibitors on Prognosis of Transplant Kidney PatientsCondition 1: Diabetes mellitus type 2. Condition 2: Transplant Kidney.Type 2 diabetes mellitus with kidney complicationsKidney transplant statusE11.2Z94.0IRCT20220708055414N1Orchidpharmed30
Completed
Not Applicable
ong-term renoprotective effect of SGLT2 inhibitorstype 2 diabetes melllitusJPRN-UMIN000034387ephrology Division, JA Toride Medical Center60